Lobe Sciences Ltd. LOBEF
OTC PK
| 05/31/2026 | 02/28/2026 | 11/30/2025 | 08/31/2025 | 05/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.15% | 110.06% | -27.43% | 287.66% | 95.44% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.42% | 291.85% | 122.43% | 188.77% | 186.09% |
| Operating Income | -14.42% | -291.85% | -122.43% | -188.77% | -186.09% |
| Income Before Tax | -2.95% | -253.71% | -60.72% | 20.66% | -157.69% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.95% | -253.71% | -60.72% | 21.58% | -157.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 316.26% | -- | -- | -- | -- |
| Net Income | 44.94% | -164.14% | -12.75% | 31.59% | -123.53% |
| EBIT | -14.42% | -291.85% | -122.43% | -188.77% | -186.09% |
| EBITDA | -- | -- | -- | -185.44% | -204.40% |
| EPS Basic | 61.11% | -84.62% | 26.47% | -323.23% | -33.33% |
| Normalized Basic EPS | 85.71% | -26.32% | 47.62% | -1,456.31% | -23.53% |
| EPS Diluted | 61.11% | -84.62% | 26.47% | -323.23% | -33.33% |
| Normalized Diluted EPS | 85.71% | -26.32% | 47.62% | -1,456.31% | -23.53% |
| Average Basic Shares Outstanding | 44.09% | 44.60% | 53.83% | -83.83% | 68.66% |
| Average Diluted Shares Outstanding | 44.09% | 44.60% | 53.83% | -83.83% | 68.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |